By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


OSI Pharmaceuticals, Inc. 

A Wholly-Owned Subsidiary of Astellas US LLC
One Bioscience Park Drive
Farmingdale  New York  11735  U.S.A.
Phone: 631-962-2000 Fax: 631-752-3880


About OSI Pharmaceuticals

OSI Pharmaceuticals, acquired by Astellas Pharma Inc. in 2010, is a leading biotechnology company focused on the discovery and development of high-quality, next-generation oncology products to both extend and improve the lives of cancer patients worldwide. The acquisition of OSI is expected to augment Astellas' strong existing franchises in urology and transplantation, expanding the product portfolio and pipeline of the combined company. OSI serves as Astellas’ small molecule research arm and focuses on developing mechanism-based approaches to drug discovery directed at the processes underlying the role of the Epithelial Mesenchymal Transition in the development of cancer. OSI has a balanced pipeline of oncology drug candidates that includes both mechanism-based, gene-targeted therapies focused in the areas of signal transduction and apoptosis and next-generation cytotoxic chemotherapy agents. OSI discovered and developed Tarceva® (erlotinib), a leading cancer medication, and has several prospective new oncology candidates in the R&D pipeline.

For additional information about the company, please visit

Company Contact Information
Maribeth Landwehr, Director
Corporate Communications

Key Statistics

Ownership: Subsidiary

Web Site: OSI Pharma
Symbol: OSIP


Company News
Genentech (RHHBY), OSI Pharma (OSIP) to Fork Over $67 Million for Misleading Info About Cancer Drug Efficacy 6/7/2016 6:51:31 AM
Astellas Pharma Inc. (YPH.BE) Shuts Down OSI Pharmaceuticals, Inc. (OSIP), Perseid in Restructuring of R&D Ops, Cuts 200 Jobs 5/14/2013 8:02:02 AM
PanOptica, Inc. Appoints Colin Goddard, Former CEO of OSI Pharmaceuticals, Inc. (OSIP), to Board of Directors 4/1/2011 8:14:37 AM
AVEO Pharmaceuticals, Inc. (AVEO) to Get $25 Million in Milestone Payments from OSI Pharmaceuticals, Inc. (OSIP) 12/1/2010 8:19:03 AM
Astellas Pharma Inc. (YPH.BE) Keeping 90 OSI Pharmaceuticals, Inc. (OSIP) Jobs on Long Island 10/6/2010 7:19:48 AM
OSI Pharmaceuticals, Inc. (OSIP) Announces the Results of its Offer to Purchase its 2% Convertible Notes and a Change in the Expiration Time of its Offer to Purchase its 3% Convertible Notes 7/14/2010 8:17:45 AM
OSI Pharmaceuticals, Inc. (OSIP) Announces Occurrence of a Fundamental Change for Convertible Notes 6/18/2010 1:35:35 PM
OSI Pharmaceuticals, Inc. (OSIP) Announces Occurrence of a Fundamental Change for Convertible Notes 6/10/2010 10:35:49 AM
Astellas Pharma Inc. Completes Acquisition of OSI Pharmaceuticals, Inc. (OSIP) 6/9/2010 11:34:27 AM
Astellas Pharma Inc. Announces Successful Completion of Tender Offer for Shares of OSI Pharmaceuticals, Inc. (OSIP) 6/8/2010 8:35:51 AM